1. Resolute all comers trial Objective:To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study:Multicenter, single blind, randomized non- inferiority trial. Population:Patients with stable CAD and ACS (NSTEMI, STEMI, UA). Size 2.25-4 mm. No restrictions on no of stents, no of treated lesions, lesion length, treated vessel Endpoint: TLF: cardiac death, MI, clinically driven TLR at 1 year f-up. Objective:To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study:Multicenter, single blind, randomized non- inferiority trial. Population:Patients with stable CAD and ACS (NSTEMI, STEMI, UA). Size 2.25-4 mm. No restrictions on no of stents, no of treated lesions, lesion length, treated vessel Endpoint: TLF: cardiac death, MI, clinically driven TLR at 1 year f-up.

2. Patients enrolled N=2292 Zotarolimus DES (Endeavor- Resolute) N=1140 Everolimus DES (Xience V) N=1152 Planned f-up angio 13 m. 20% of patients Planned f-up angio 13 m. 20% of patients Resolute all comers trial

3. p=0.92p=0.50p=0.08p=0.94p=0.01 Event rate at 1 year f-up (%) Resolute all comers trial

4. Late loss (mm)QCA at 13 months f-up angio Resolute all comers trial

5. Serruys et al. N Engl J Med 2010;363:136-46 Conclusion:At follow-up the new generation ZES (Endeavor-Resolute) was found to be non- inferior to the everolimus eluting Xience V stent in a population of patients with minimal exclusion criteria. Resolute all comers trial